BlackRock Bieshin Wealth Management Besheng Multi-Asset Fixed Income Product, 36 periods, issued starting April 2nd, with a performance benchmark of 2.2% - 3.7%

LightningPacketLoss · 2026-04-02T05:31:50+00:00

BlackRock Jianxin Wealth Management will issue 36 fixed-income financial products from April 2 to April 9, 2026. The minimum subscription amount is 1 yuan, with a maximum scale of 200 million yuan. The risk rating is medium risk, with a term of 558 days, and a performance benchmark of 2.20%–3.70%. Investment is subject to risk.

LightningPacketLoss

2026-04-02 05:31:50

Abstract generation in progress

On April 2, according to a disclosure by BlackRock CCB Wealth Management, the subscription period for the 36th issuance of its Besheng Multi-Asset Allocation Fixed-Income Wealth Management Product (closed-end) is from April 2, 2026 to April 9, 2026. The minimum subscription amount starts at 1 yuan. The product’s upper limit on total size is no more than 200 million yuan, and the lower limit on total size is not less than 10 million yuan. The product type is fixed-income. The internal risk rating of the product is R3 (medium risk). The product term is 558 days. Performance comparison benchmark: 2.20%-3.70% (annualized) at product maturity.

Note: The performance comparison benchmark is not a forecast of returns, does not represent the product’s future performance and actual returns, and does not constitute a commitment regarding the product’s收益.

The above information about the wealth management products is for reference only. The specific details shall be subject to sales documents such as the “Product Prospectus.” This article does not constitute any investment advice. Investors act at their own risk.

(China Wealth Management Network)

(Editor: Qian Xiaorui)

Keywords:

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.